EphB4 as a therapeutic target in mesothelioma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Liu, Ren ^a   Ferguson, Benjamin D ^b   Zhou, Yue ^a   Naga, Kranthi ^c   Salgia, Ravi ^b   Gill, Parkash S ^a   Krasnoperov, Valery ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Vasgene Therapeutics Inc   (United States)

Author keywords

Cancer therapy; EphB4; Mesothelioma; SEphB4

Indexed keywords

BEVACIZUMAB; EPHRIN B4; EPHRIN B4 HUMAN SERUM ALBUMIN FUSION PROTEIN; HYBRID PROTEIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPHRIN RECEPTOR B4; MONOCLONAL ANTIBODY; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MALIGNANT MESOTHELIOMA; MONOTHERAPY; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG DELIVERY SYSTEM; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; METABOLISM; NICK END LABELING; PLEURA TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; PLEURAL NEOPLASMS; RECEPTOR, EPHB4; SERUM ALBUMIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878258020     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-269     Document Type: Article

References (33)

1. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002, 29(1):2-17.
2. Chen SE, Pace MB. Malignant pleural mesothelioma. Am J Health Syst Pharm 2012, 69(5):377-385. 10.2146/ajhp110281, 22345416.
3. Cao C, Yan TD, Bannon PG, McCaughan BC. Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 2011, 18(10):2973-2979. 10.1245/s10434-011-1728-x, 21512863.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644. 10.1200/JCO.2003.11.136, 12860938.
5. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012, 77(3):567-571. 10.1016/j.lungcan.2012.05.111, 22770372.
6. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30(20):2509-2515. 10.1200/JCO.2011.41.5869, 22665541.
7. Gerety SS, Anderson DJ. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 2002, 129(6):1397-1410.
8. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999, 4(3):403-414. 10.1016/S1097-2765(00)80342-1, 10518221.
9. Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA, Anderson DJ. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 2001, 230(2):139-150. 10.1006/dbio.2000.9957, 11161568.
10. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, Follenzi A, Tosato G. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 2009, 114(8):1707-1716. 10.1182/blood-2008-12-192294, 2731645, 19411631.
11. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010, 465(7297):487-491. 10.1038/nature08995, 20445540.
12. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Canamero M, Ortega S, Megias D, Rodriguez A, Martinez-Torrecuadrada JL. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012, 119(19):4565-4576. 10.1182/blood-2011-09-380006, 22446484.
13. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465(7297):483-486. 10.1038/nature09002, 20445537.
14. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009, 113(1):254-263. 10.1182/blood-2008-02-140020, 2614637, 18836096.
15. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006, 169(1):279-293. 10.2353/ajpath.2006.050889, 1698769, 16816380.
16. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res 2005, 65(11):4623-4632. 10.1158/0008-5472.CAN-04-2667, 15930280.
17. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 2007, 96(7):1083-1091. 10.1038/sj.bjc.6603642, 2360128, 17353927.
18. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004, 10(1):26-33. 10.1007/BF02893405, 15029258.
19. Lee YC, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG, Stephenson SA. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer 2005, 5:119. 10.1186/1471-2407-5-119, 1266025, 16171530.
20. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010, 9(8):2377-2388. 10.1158/1535-7163.MCT-10-0200, 2933364, 20682653.
21. Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 2006, 119(6):1236-1248. 10.1002/ijc.21926, 16615113.
22. Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006, 132(10):1053-1059. 10.1001/archotol.132.10.1053, 17043250.
23. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers. Cancer Res 2013, 73(1):184-194. 10.1158/0008-5472.CAN-12-0915, 23100466.
24. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 2005, 11(12):4305-4315. 10.1158/1078-0432.CCR-04-2109, 15958611.
25. Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J 2006, 25(6):1242-1252. 10.1038/sj.emboj.7601031, 1422162, 16511561.
26. Palmer A, Zimmer M, Erdmann KS, Eulenburg V, Porthin A, Heumann R, Deutsch U, Klein R. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell 2002, 9(4):725-737. 10.1016/S1097-2765(02)00488-4, 11983165.
27. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS. Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth. Am J Pathol 2010, 176(4):2029-2038. 10.2353/ajpath.2010.090755, 2843490, 20133814.
28. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006, 107(6):2330-2338. 10.1182/blood-2005-04-1655, 1895726, 16322467.
29. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci 2012, 101(6):1969-1984. 10.1002/jps.23096, 22411527.
30. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, Duarte A. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 2010, 10(1):641. 10.1186/1471-2407-10-641, 3001720, 21092311.
31. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report 2009, 2(2):181-188.
32. Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs 2011, 22(1):79-88. 10.1097/CAD.0b013e32833f44fd, 20881478.
33. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003, 104(5):603-610. 10.1002/ijc.10996, 12594815.